Karnataka Health Minister Dinesh Gundu Rao has said that some high-value medicines used in cancer, kidney and HIV treatment are being sold at prices as high as 70 times the procurement cost, a disclosure that has renewed scrutiny of India's hospital drug pricing system and the wide gap between what institutions pay and what patients are charged.
The minister's remarks point to a structural problem that extends beyond a single state: the absence of transparent, standardised disclosure across the pharmaceutical supply chain. In his call for a national study, Rao sought a comparison of four separate price points — the printed maximum retail price, the manufacturer or importer price, the hospital's net acquisition cost, and the final bill presented to patients. That comparison, if undertaken systematically, would expose how much value is added at each stage and where markups become excessive.
Pricing Gaps Exposed
Rao's intervention is significant because it shifts the debate from isolated complaints about expensive medicines to the mechanics of pricing itself. In India, patients often encounter a single final bill, with little visibility into how much the hospital paid for the drug, whether discounts were negotiated, or whether the billed amount reflects procurement cost or a much higher retail benchmark. For life-saving therapies, that opacity can be devastating, especially for families already facing prolonged treatment cycles.
The minister's reference to cancer, kidney and AIDS medicines underscores the sensitivity of the issue. These are not discretionary purchases; they are often essential, repeated and time-bound, which gives suppliers and hospitals considerable pricing power. When procurement is opaque, the patient has limited bargaining leverage and little ability to verify whether the charge is justified. The result is a system in which the printed MRP may become a ceiling in theory, but in practice can still serve as the basis for substantial markups.
Call For National Study
By asking for a national study, Rao has effectively argued that the issue cannot be addressed through anecdotal cases alone. A credible audit would need to examine selected high-value medicines, medical devices and consumables across public and private institutions, and then map the relationship between procurement price and patient billing. Such a study could also reveal whether hospitals are passing on procurement efficiencies to patients or retaining the spread as revenue.
The proposal is also politically important because it touches on a broader public health concern: India's high out-of-pocket expenditure on healthcare. Even where insurance coverage exists, patients frequently face co-payments, exclusions or charges for items not fully covered by policy. In that environment, inflated billing on essential medicines can quickly push households into financial distress. A national comparison of price layers would therefore not only test hospital billing practices but also help policymakers assess whether current price controls and procurement rules are adequate.
The minister's remarks are likely to resonate with consumer groups, health economists and patient advocates who have long argued that medicine pricing in India remains too opaque. They have often pointed out that the same drug can be procured at very different rates depending on the institution, volume, supplier relationship and tender process, yet patients rarely see any of that variation reflected in their final bill.
Policy Pressure Rises
The immediate policy question is whether the Centre and states will move toward mandatory disclosure of procurement and billing data for selected categories of medicines and devices. If hospitals were required to publish acquisition prices alongside patient charges, it would become easier to identify unjustified spreads and benchmark fair margins. It would also create pressure for more disciplined procurement, especially in high-cost therapeutic areas where price variation is largest.
Rao's statement arrives at a time when healthcare affordability remains a major governance challenge. India has expanded access to treatment in many areas, but the cost burden on patients remains uneven and often unpredictable. The minister's demand for a national study suggests that the next frontier in health reform may not be only about expanding coverage, but about making the pricing chain itself transparent enough to withstand public scrutiny.
If the figures cited by the minister are borne out by a formal review, the implications would be far-reaching. It would strengthen the case for tighter price disclosure norms, stronger procurement oversight and clearer billing standards across hospitals. More broadly, it would force a national conversation on whether essential medicines should be treated as a public-interest good with far greater pricing transparency than the current system provides.